Depression is a mental health issue. It’s a condition that starts most often in early adulthood. It’s also more common in women. However, anyone at any age may suffer from depression. Depression affects the brain, so drugs that work in the brain may offer hope. Common antidepressants may help ease your symptoms, but there are many other options as well. Each drug used to treat depression works by balancing certain chemicals in your brain called neurotransmitters. Depression Drugs is drugs used for Depression.
This report contains market size and forecasts of Depression Drugs in Global, including the following market information:
Global Depression Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Depression Drugs market was valued at 17630 million in 2021 and is projected to reach US$ 21350 million by 2028, at a CAGR of 2.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
SSRIs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Depression Drugs include Intellipharmaceutics, Pfizer, Eli Lilly, Astrazeneca, Lundbeck, Allergan, GSK, Otsuka Pharmaceutical and Takeda, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Depression Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Depression Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Depression Drugs Market Segment Percentages, by Type, 2021 (%)
SSRIs
SNRIs
Others
Global Depression Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Depression Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Depression Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Depression Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Depression Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Depression Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Intellipharmaceutics
Pfizer
Eli Lilly
Astrazeneca
Lundbeck
Allergan
GSK
Otsuka Pharmaceutical
Takeda
NHU Group
Shionogi
APOTEX
Kanghong Pharma
HUAHAI